SCHEMBL4486069

SCHEMBL4486069

CN1CCN(C(=O)N(C)c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.57
HPGD P15428 2/20 0.57
MEN1 O00255 2/20 0.52
GAA P10253 2/20 0.52
KMT2A Q03164 2/20 0.52
SIRT6 Q8N6T7 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
AR P10275 2/20 0.47
MAPK1 P28482 1/20 0.47
LMNA P02545 1/20 0.47
HRH4 Q9H3N8 2/20 0.46
FAAH O00519 1/20 0.44
MGLL Q99685 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1361808 0.82 ALDH1A1 (0.50) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL28411789 0.81 ALDH1A1 (0.52) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL15134846 0.80 KMT2A (0.65) ALDH1A1MEN1GAAKMT2ALMNA
SCHEMBL4492896 0.80 SIRT6 (0.48) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL4492860 0.79 GAA (0.49) ALDH1A1MEN1GAAKMT2ALMNA
SCHEMBL18390307 0.79 GAA (0.64) ALDH1A1MEN1GAAKMT2AL3MBTL1
SCHEMBL18390285 0.77 MAPT (0.55) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL110101 0.76 ALDH1A1 (0.72) ALDH1A1HPGDMEN1GAAKMT2A
SCHEMBL3534751 0.76 ALDH1A1 (0.59) ALDH1A1MEN1GAAKMT2AL3MBTL1
SCHEMBL4490094 0.75 ALDH1A1 (0.50) ALDH1A1HPGDMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR ALDH1A1 2036/4885HPGD 2420/4885MEN1 1288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.